212 related articles for article (PubMed ID: 10980903)
1. Oral platelet glycoprotein IIb/IIIa inhibition.
Newby LK; McGuire DK
Curr Cardiol Rep; 2000 Sep; 2(5):372-7. PubMed ID: 10980903
[TBL] [Abstract][Full Text] [Related]
2. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
3. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
Newby LK
Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
[TBL] [Abstract][Full Text] [Related]
4. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Chew DP; Bhatt DL; Sapp S; Topol EJ
Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677
[TBL] [Abstract][Full Text] [Related]
5. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Cannon CP
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-14-7. PubMed ID: 11129681
[TBL] [Abstract][Full Text] [Related]
6. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
Chew DP; Bhatt DL
Curr Cardiol Rep; 2001 Jan; 3(1):63-71. PubMed ID: 11139801
[TBL] [Abstract][Full Text] [Related]
7. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Sabatine MS; Jang IK
Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
[TBL] [Abstract][Full Text] [Related]
8. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
McGuire DK; Newby LK
J Thromb Thrombolysis; 2000 Oct; 10(2):111-9. PubMed ID: 11005932
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
Ault KA; Cannon CP; Mitchell J; McCahan J; Tracy RP; Novotny WF; Reimann JD; Braunwald E
J Am Coll Cardiol; 1999 Mar; 33(3):634-9. PubMed ID: 10080462
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
[TBL] [Abstract][Full Text] [Related]
11. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa antagonists: do they have a role in the management of unstable angina?
Redwood S; Marber M; Jackson G
Int J Clin Pract; 1999 Dec; 53(8):618-22. PubMed ID: 10692757
[TBL] [Abstract][Full Text] [Related]
13. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
Liu F; Craft RM; Morris SA; Carroll RC
Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
[TBL] [Abstract][Full Text] [Related]
14. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
Vorchheimer DA; Badimon JJ; Fuster V
JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
[TBL] [Abstract][Full Text] [Related]
16. New antiplatelet agents.
White HD; French JK; Ellis CJ
Aust N Z J Med; 1998 Aug; 28(4):558-64. PubMed ID: 9777140
[TBL] [Abstract][Full Text] [Related]
17. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
Topol EJ; Easton JD; Amarenco P; Califf R; Harrington R; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Willerson JT; Chan R; Samuels R; Ilson B; Granett J
Am Heart J; 2000 Jun; 139(6):927-33. PubMed ID: 10827369
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
[TBL] [Abstract][Full Text] [Related]
19. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
Dobesh PP; Latham KA
Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
[TBL] [Abstract][Full Text] [Related]
20. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
